Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Vaia Florou; Andrew E Rosenberg; Eric Wieder; Krishna V Komanduri; Despina Kolonias; Mohamed Uduman; John C Castle; Jennifer S Buell; Jonathan C Trent; Breelyn A Wilky

doi:10.1186/s40425-019-0792-9

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

J Immunother Cancer. 2019 Nov 6;7(1):285. doi: 10.1186/s40425-019-0792-9.

Affiliations

¹ Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA. [email protected].
² Department of Medicine, Division of Oncology, Sylvester Comprehensive Cancer Center at University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
³ Agenus Inc., 3 Forbes Road, Lexington, MA, 02421, USA.

Abstract

Following publication of the original article [1], the authors have reported that the following sentence "While of the same IgG1 class as ipilimumab, preclinical data suggests this molecule may have enhanced activity against T regulatory cells".

Publication types

Published Erratum